A unique health supplement could give fresh hope to those living with Irritable Bowel Syndrome (IBS) as trials reveal it can reduce symptoms of the chronic condition, affecting up to one in five of the UK population1.

"Second generation" galactooligosaccharide Bimuno® was found to reduce abdominal pain and bloating, ease bowel movements and improve stool consistency in those diagnosed with IBS.

The clinical study, published in the Alimentary Pharmacology & Therapeutics, is the result of a joint study from the Imperial College Healthcare NHS Trust, Central Middlesex Hospital and the University of Reading.

Results of the study showed a reduction in symptoms of IBS for those patients taking Bimuno, including bloating and abdominal pain, with some also reporting reduced anxiety scores and better quality of life.

Professor David Silk, Consultant Gastroenterologist and principle investigator of the study said: "This is a very exciting study as it shows that Bimuno offers IBS sufferers a non medicinal and nutritional option in the management of this very common and often chronic condition"…